| Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (NCT02005458) | Xiamen Amoytop Biotech Co., Ltd. | 2013-12-01 |
| The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections (NCT02840227) | The Cleveland Clinic | 2013-12-01 |
| Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (NCT02162537) | Centre Hospitalier Intercommunal Creteil | 2013-12-01 |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (NCT01999673) | Peregrine Pharmaceuticals | 2013-12-01 |
| Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression (NCT01998061) | Zhejiang University | 2013-12-01 |
| A Prospective Epidemiologic Study of ALK-Positive NSCLC in China (NCT02042105) | Guangdong Association of Clinical Trials | 2013-11-11 |
| Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (NCT01928576) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-11-06 |
| A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation (NCT01728181) | University of Utah | 2013-11-01 |
| A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis (NCT02803619) | Peking Union Medical College Hospital | 2013-11-01 |
| Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer (NCT01837329) | University of Rochester | 2013-11-01 |
| CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer (NCT02764606) | Hospices Civils de Lyon | 2013-11-01 |
| Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²) (NCT02448758) | Centre Oscar Lambret | 2013-11-01 |
| Genomic Investigation of Unusual Responders (NCT03740503) | University Health Network, Toronto | 2013-11-01 |
| A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-11-01 |
| Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor (NCT01947868) | AstraZeneca | 2013-11-01 |
| A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (NCT02000947) | MedImmune LLC | 2013-10-25 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer (NCT01967823) | National Cancer Institute (NCI) | 2013-10-24 |
| Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients (NCT01882621) | Sun Yat-sen University | 2013-10-01 |
| Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer (NCT02075957) | University Hospital, Angers | 2013-10-01 |
| Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB (NCT02001168) | Xinjiang Medical University | 2013-10-01 |
| Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (NCT02568033) | The Cooper Health System | 2013-10-01 |
| A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (NCT01871805) | Hoffmann-La Roche | 2013-09-30 |
| Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC (NCT01945021) | Pfizer | 2013-09-30 |
| Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression (NCT01977209) | Third Military Medical University | 2013-09-01 |
| Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer (NCT02262000) | West Virginia University | 2013-09-01 |
| Ponatinib in Advanced NSCLC w/ RET Translocations (NCT01813734) | Massachusetts General Hospital | 2013-09-01 |
| Value of Physical Capacity Tests in Lung Cancer (NCT01943578) | Rigshospitalet, Denmark | 2013-09-01 |
| Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer (NCT01951690) | Verastem, Inc. | 2013-09-01 |
| Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (NCT01831089) | PharmaMar | 2013-09-01 |
| Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC (NCT01913067) | Jules Bordet Institute | 2013-09-01 |
| A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" (NCT01903993) | Hoffmann-La Roche | 2013-08-06 |
| Metformin in Stage IV Lung Adenocarcinoma (NCT01997775) | National Cheng-Kung University Hospital | 2013-08-01 |
| Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy (NCT02728492) | NewVac LLC | 2013-08-01 |
| Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302） (NCT01924195) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2013-08-01 |
| Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study (NCT01887795) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2013-08-01 |
| Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients (NCT02113852) | Guangdong Association of Clinical Trials | 2013-08-01 |
| Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation (NCT01929200) | Betta Pharmaceuticals Co., Ltd. | 2013-08-01 |
| Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) (NCT01918761) | Central European Cooperative Oncology Group | 2013-07-30 |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (NCT01828099) | Novartis Pharmaceuticals | 2013-07-09 |
| Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer (NCT01899989) | Memorial Sloan Kettering Cancer Center | 2013-07-05 |
| A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer (NCT01858389) | Pfizer | 2013-07-01 |
| Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (NCT01854034) | Massachusetts General Hospital | 2013-07-01 |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (NCT01828112) | Novartis Pharmaceuticals | 2013-06-28 |
| Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC (NCT01783197) | Canadian Cancer Trials Group | 2013-06-04 |
| VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer (NCT01891708) | Li Liu | 2013-06-01 |
| Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy (NCT01902875) | Jinling Hospital, China | 2013-06-01 |
| Treating NSCLC Minimal Stage IV With Curative Intent (NCT02054819) | Leo W. Jenkins Cancer Center | 2013-06-01 |
| Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (NCT01772797) | Novartis Pharmaceuticals | 2013-06-01 |
| Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases (NCT01926171) | Betta Pharmaceuticals Co., Ltd. | 2013-06-01 |
| Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy (NCT01891123) | Sun Yat-sen University | 2013-06-01 |
| Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer (NCT01880528) | Mayo Clinic | 2013-05-31 |
| A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] (NCT01846416) | Genentech, Inc. | 2013-05-30 |
| Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors (NCT01803503) | National University Hospital, Singapore | 2013-05-01 |
| Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) (NCT01833572) | Fudan University | 2013-05-01 |
| Correlation Research of Thioredoxin Reductase in Lung Cancer (NCT01985113) | Hunan Province Tumor Hospital | 2013-05-01 |
| CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer (NCT01871480) | Kunming Medical University | 2013-05-01 |
| Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (NCT01840579) | Merck Sharp & Dohme LLC | 2013-04-26 |
| Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D (NCT01833143) | Memorial Sloan Kettering Cancer Center | 2013-04-11 |
| A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (NCT01789099) | Ultimovacs ASA | 2013-04-08 |
| Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer (NCT01836679) | Chipscreen Biosciences, Ltd. | 2013-04-01 |
| Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation (NCT01836341) | Memorial Sloan Kettering Cancer Center | 2013-04-01 |
| Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® (NCT01820091) | Acrotech Biopharma Inc. | 2013-04-01 |
| A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer (NCT01792479) | BIND Therapeutics | 2013-04-01 |
| Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients (NCT01843647) | Betta Pharmaceuticals Co., Ltd. | 2013-04-01 |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (NCT01803282) | Gilead Sciences | 2013-03-29 |
| Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (NCT01820754) | Duke University | 2013-03-01 |
| A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer (NCT01788566) | Eli Lilly and Company | 2013-03-01 |
| CTP Imaging of Lung Cancer (NCT01823094) | University of California, Davis | 2013-03-01 |
| Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer (NCT01885754) | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | 2013-02-01 |
| Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer (NCT01774578) | NewLink Genetics Corporation | 2013-02-01 |
| Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer (NCT01676714) | University of California, Davis | 2013-02-01 |
| A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers (NCT01860508) | Fudan University | 2013-02-01 |
| Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy (NCT01720901) | Betta Pharmaceuticals Co., Ltd. | 2013-02-01 |
| Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens (NCT01799382) | Maggiore Bellaria Hospital, Bologna | 2013-02-01 |
| Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NCT01647334) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2013-01-01 |
| Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC (NCT01771289) | Peking University People's Hospital | 2013-01-01 |
| Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer (NCT01767974) | Chonnam National University Hospital | 2013-01-01 |
| AUY922 for Advanced ALK-positive NSCLC (NCT01752400) | Massachusetts General Hospital | 2013-01-01 |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer (NCT01685138) | Novartis Pharmaceuticals | 2012-12-20 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (NCT01631552) | Gilead Sciences | 2012-12-17 |
| Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 (NCT01714908) | Jinming Yu | 2012-12-14 |
| Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) (NCT01573702) | UNC Lineberger Comprehensive Cancer Center | 2012-12-11 |
| Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC (NCT02488850) | Erasmus Medical Center | 2012-12-01 |
| Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC (NCT01753414) | Radiation Therapy Oncology Group | 2012-12-01 |
| Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC (NCT01755923) | Peking Union Medical College Hospital | 2012-12-01 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC (NCT01772732) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2012-12-01 |
| Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer (NCT01398124) | Milton S. Hershey Medical Center | 2012-12-01 |
| LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (NCT01685060) | Novartis Pharmaceuticals | 2012-11-26 |
| Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LARTIA Trial) (NCT03583723) | Campus Bio-Medico University | 2012-11-02 |
| Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases (NCT01763385) | Wu Jieping Medical Foundation | 2012-11-01 |
| Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) (NCT01799135) | Dana-Farber Cancer Institute | 2012-11-01 |
| MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NCT01628471) | Uman Pharma | 2012-11-01 |
| A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NCT01630733) | Achieve Life Sciences | 2012-10-24 |
| Pilot Study of Regional Lung Ventilation (NCT03077113) | H. Lee Moffitt Cancer Center and Research Institute | 2012-10-15 |
| Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (NCT01724801) | Guangdong Association of Clinical Trials | 2012-10-14 |
| Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer (NCT01522833) | SCRI Development Innovations, LLC | 2012-10-01 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung (NCT01872403) | The First Affiliated Hospital of Guangzhou Medical University | 2012-10-01 |
| Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy (NCT01746277) | Peking Union Medical College Hospital | 2012-10-01 |
| Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR (NCT01744925) | Tianjin Medical University Cancer Institute and Hospital | 2012-10-01 |
| A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer (NCT01763645) | Biocad | 2012-10-01 |